N-(2-甲基-6-苯并噻唑基)-乙酰胺 | 68867-19-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: N-(2-甲基-6-苯并噻唑基)-乙酰胺
• 中文别名: (9ci)-n-(2-甲基-6-苯并噻唑)-乙酰胺
• 英文名称: 6-acetamido-2-methylbenzothiazole
• 英文别名: N-(2-methylbenzo[d]thiazol-6-yl)acetamide；N-(2-methyl-1,3-benzothiazol-6-yl)acetamide；6-Acetylamino-2-methyl-benzo<1,3>thiazol；6-Acetamino-2-methyl-benzthiazol；N-(2-Methyl-benzothiazol-6-yl)-acetamid；N-(2-methyl-benzothiazol-6-yl)acetamide；2-methyl-6-acetamido-benzothiazole
• CAS: 68867-19-6
• 化学式: C₁₀H₁₀N₂OS
• mdl: MFCD00656936
• 分子量: 206.268
• InChiKey: XLYNOVXELOHZDY-UHFFFAOYSA-N

物化性质

• 熔点：
  145-147 °C
• 沸点：
  429.7±18.0 °C(Predicted)
• 密度：
  1.325±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  70.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934200090

反应信息

• 作为反应物：
  描述：

  N-(2-甲基-6-苯并噻唑基)-乙酰胺 在 盐酸 、 sodium hydroxide 、 tin 、 硫酸 、 硝酸 作用下， 生成 2-methyl-1,3-benzothiazol-7-amine
  参考文献：
  名称：

  Mizuno; Adachi, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1952, vol. 72, p. 739,742

  摘要：

  DOI：
• 作为产物：
  描述：

  N,N'-(iodo-p-phenylene)-bis-acetamide 在 copper(l) iodide 、 sodiumsulfide nonahydrate 、 盐酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 以81%的产率得到N-(2-甲基-6-苯并噻唑基)-乙酰胺
  参考文献：
  名称：

  替代苯并噻唑的有效和经济途径：2-卤代苯胺与金属硫化物的铜催化偶联和随后的缩合

  摘要：

  不要告诉唑：金属硫化物与芳基卤化物的首次金属催化直接偶联，以及随后的分子内缩合提供了取代的苯并噻唑（参见方案）。在反应条件下可耐受多种官能团。

  DOI：

  10.1002/anie.200900486

文献信息

• [EN] NOVEL GALACTOSIDE INHIBITOR OF GALECTINS<br/>[FR] NOUVEL INHIBITEUR GALACTOSIDE DE GALECTINES
  申请人：GALECTO BIOTECH AB

  公开号：WO2021004940A1

  公开（公告）日：2021-01-14

  The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is beta-D-galactopyranose, and these compounds are high affinity galectin-1 and/or 3 inhibitors for use in treatment of inflammation; Inflammation induced thrombosis; Atopic dermatitis; Acute coronary syndrome; fibrosis, such as pulmonary fibrosis, liver fibrosis, kidney fibrosis, ophthalmological fibrosis and fibrosis of the skin and heart; local fibrosis such as Dupuytren's disease and Peyronie's disease; fibrotic complications of other therapies such as coronary stents, bile duct stents, cerebral artery stents, ureter stents; scleroderma; scarring; keloid formation; covid-19; acute lung injury; ARDS; viral pneumonitis, aberrant scar formation; surgical adhesions; septic shock; cancer, such as colorectal cancer, other gastrointestinal carcinomas such as pancreatic cancer, gastric cancer, biliary tract cancer, lung cancers, mesothelioma, female cancers like breast cancer, ovarian cancer, uterine cancer, cancer of the cervix uteri, cancer of the salpingx, cerebral cancers such as medulloblastomao, glioma, meningioma, sarcomas of the bones and muscles and other sarcomas, leukemias and lymphomas, such as T-cell lymphomas; transplant rejection; metastasising cancers; ageing; Dementia; Alzheimers; TGFbeta driven bone disease such as osteogenesis imperfecta; Pulmonary hypertension; autoimmune diseases, such as psoriasis, rheumatoid arthritis, Rheumatoid lung; Crohn's disease, ulcerative colitis, ankylosing spondylitis, systemic lupus erythematosus; viral infections such as influenza virus, HIV, Herpes virus, Coronaviruses, Hepatitis C; metabolic disorders; heart disease; heart failure; pathological angiogenesis, such as ocular angiogenesis or a disease or condition associated with ocular angiogenesis, e.g. neovascularization related to cancer; and eye diseases, such as age-related macular degeneration and corneal neovascularization; atherosclerosis; metabolic diseases; diabetes; type I diabetes; type 2 diabetes; insulin resistens; obesity; Marfans syndrome; Loeys–Dietz syndrome; nephropathy; Diastolic HF; fibrotic lung complications of aPD1 and other CPI therapies; asthma and other interstitial lung diseases, including Hermansky-Pudlak syndrome, liver disorders, such as non- alcoholic steatohepatitis or non-alcoholic fatty liver disease; uterine disease such as uterine fibroids and uterine or cervical fibrosis.

  本发明涉及一种化学式（1）中的D-半乳糖吡喃糖类化合物，其中吡喃糖环为β-D-半乳糖吡喃糖，并且这些化合物是高亲和力的galectin-1和/或3抑制剂，用于治疗炎症；炎症诱导性血栓形成；特应性皮炎；急性冠状动脉综合征；纤维化，如肺纤维化、肝纤维化、肾脏纤维化、眼科纤维化和皮肤和心脏的纤维化；局部纤维化，如杜普伊特伦氏病和佩龙氏病；其他治疗的纤维化并发症，如冠状支架、胆管支架、脑动脉支架、输尿管支架；硬皮病；瘢痕形成；瘢痕增生；新冠肺炎；急性肺损伤；ARDS；病毒性肺炎；异常瘢痕形成；手术粘连；脓毒性休克；癌症，如结直肠癌、其他胃肠癌，如胰腺癌、胃癌、胆道癌、肺癌、间皮瘤、女性癌症如乳腺癌、卵巢癌、子宫癌、宫颈癌、输卵管癌、脑癌如髓母细胞瘤、胶质瘤、脑膜瘤、骨骼和肌肉的肉瘤和其他肉瘤、白血病和淋巴瘤，如T细胞淋巴瘤；移植排斥；转移性癌症；衰老；痴呆症；阿尔茨海默病；TGFbeta驱动的骨疾病，如骨发育不全；肺动脉高压；自身免疫疾病，如牛皮癣、类风湿关节炎、类风湿肺；克罗恩病、溃疡性结肠炎、强直性脊柱炎、系统性红斑狼疮；病毒感染，如流感病毒、HIV、疱疹病毒、冠状病毒、丙型肝炎；代谢紊乱；心脏病；心力衰竭；病理性血管生成，如眼部血管生成或与眼部血管生成相关的疾病或症状，例如与癌症相关的新血管生成；眼部疾病，如老年性黄斑变性和角膜新血管生成；动脉粥样硬化；代谢性疾病；糖尿病；1型糖尿病；2型糖尿病；胰岛素抵抗；肥胖；马凡氏综合征；洛伊斯-迪茨综合征；肾病；舒张期心力衰竭；aPD1和其他CPI疗法的肺纤维化并发症；哮喘和其他间质性肺疾病，包括赫尔曼斯基-普德拉克综合征、肝脏疾病，如非酒精性脂肪性肝炎或非酒精性脂肪肝病；子宫疾病，如子宫肌瘤和子宫或宫颈纤维化。
• QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
  申请人：Cook, II James H.

  公开号：US20090270405A1

  公开（公告）日：2009-10-29

  The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

  该披露提供了公式I的化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是烟碱性α7受体的配体，可能对治疗中枢神经系统的各种疾病，特别是情感和神经退行性疾病，有用。
• Efficient and Economical Access to Substituted Benzothiazoles: Copper-Catalyzed Coupling of 2-Haloanilides with Metal Sulfides and Subsequent Condensation
  作者：Dawei Ma、Siwei Xie、Peng Xue、Xiaojing Zhang、Jinhua Dong、Yongwen Jiang

  DOI：10.1002/anie.200900486

  日期：2009.5.25

  Don′t tell azole: The first metal‐catalyzed direct coupling of metal sulfides with aryl halides and subsequent intramolecular condensation provided substituted benzothiazoles (see scheme). A wide range of functional groups are tolerated under the reaction conditions.

  不要告诉唑：金属硫化物与芳基卤化物的首次金属催化直接偶联，以及随后的分子内缩合提供了取代的苯并噻唑（参见方案）。在反应条件下可耐受多种官能团。
• [EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA REPLICATION DU VIRUS DE L'IMMUNODEFICIENCE HUMAINE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010130034A1

  公开（公告）日：2010-11-18

  Compounds of formula I wherein a, R1, R2, R3, R4, R5 and R6 are defined herein, are useful as inhibitors of HIV replication.

  式I中的化合物，其中a、R1、R2、R3、R4、R5和R6如本文所定义，可用作HIV复制抑制剂。
• Design, synthesis and photophysical studies of styryl-based push–pull fluorophores with remarkable solvatofluorochromism
  作者：Mauro Safir Filho、Sebastien Fiorucci、Anthony R. Martin、Rachid Benhida

  DOI：10.1039/c7nj03142d

  日期：——

  steady-state fluorescence emission measurements in solution and by TD-DFT calculations. The dyes presented high brightness, absorption bands in the visible range (~ 370 - 453 nm) and large solvatofluorochromism comprising all the visible spectrum, as a consequence of the strong intramolecular charge transfer (ICT) nature of their excited state.

  通过高效和实用的合成路线，从低成本的起始原料中制备了20种基于6个氨基取代的苯并噻唑的苯乙烯基推挽式染料。首先设计染料以提供有效的锚定位点用于随后的缀合。从含有给电子和吸电子基团的取代苯环到多环芳族衍生物，筛选了一系列芳基支架。还探讨了N-烷基取代的苯并噻唑对三种不同排列的诱导作用。通过溶液中的紫外可见吸收和稳态荧光发射测量以及TD-DFT计算，进行了结构与光物理关系的研究。染料呈现出高亮度，

表征谱图